Rapport Reports Positive Focal Onset Seizures Trial Results

Reuters
Sep 08
Sept 8 (Reuters) - Rapport Therapeutics Inc ::
*RAPPORT ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2A CLINICAL TRIAL OF RAP-219 IN PATIENTS WITH FOCAL ONSET SEIZURES
*RAPPORT THERAPEUTICS INC - TRIAL MEETS PRIMARY ENDPOINTS, RAP-219 WELL TOLERATED
*RAPPORT THERAPEUTICS INC - PATIENTS ACHIEVE 77.8% SEIZURE REDUCTION, 24% SEIZURE FREEDOM
*RAPPORT THERAPEUTICS INC - RAP-219 WELL-TOLERATED WITH MILD ADVERSE EVENTS
*RAPPORT THERAPEUTICS INC - PLANS END-OF-PHASE 2 MEETING WITH FDA IN Q4 2025

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 08-SEP-202510:00:00.263 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10